









The Centre for Health Economics Research and Evaluation (CHERE) was 
established in 1991.  CHERE is a centre of excellence in health economics and 
health services research. It is a joint Centre of the Faculties of Business 
and Nursing, Midwifery and Health at the University of Technology, Sydney, in 
collaboration with Central Sydney Area Health Service. It was established as a 
UTS Centre in February, 2002. The Centre aims to contribute to the development 
and application of health economics and health services research through 
research, teaching and policy support. CHERE’s research program encompasses 
both the theory and application of health economics. The main theoretical 
research theme pursues valuing benefits, including understanding what 
individuals value from health and health care, how such values should be 
measured, and exploring the social values attached to these benefits. The 
applied research  focuses on economic and the appraisal of new programs or new 
ways of delivering and/or funding services. CHERE’s teaching includes 
introducing clinicians, health services managers, public health professionals 
and others to health economic principles. Training programs aim to develop 
practical skills in health economics and health services research. Policy 
support is provided at all levels of the health care system by undertaking 
commissioned projects, through the provision of formal and informal advice as 
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Since the early 1980s it has been identified that even though economic evaluation is 
considered useful by economist it is not widely used by health care decision-makers. One 
of the ways to close the gap is to involve decision-makers in the process. This project was 
set up to gain a better understanding of the information needs for resource allocation in 
the field of cancer care.  The results of this project are intended to aid the development 
and use of the NSW Cancer Institute’s Standard Cancer Treatments (CI-SCAT) website 
in future years. This initiative is part of the NSW 2004-2006 Cancer to ensure that 
clinical practice is evidence-based and research driven. The CI-SCAT Reference Group 
develops and approves clinical protocols to provide clinicians with chemotherapy cancer 
protocols, including the evidence, cost, and drug dose calculation. Members of CI-SCAT 
Reference Groups were surveyed in their capacity as clinicians and decision-makers in 
the Australian Health Care System. The survey asked about participants’ knowledge, use 
and views of economic evaluation in decision making.  It also sought information about 
their knowledge and views on how resource allocation decisions were made within your 
local area/hospital and whether participants would value greater access to various types 
of economic information.    
 
This paper will explore what decision-makers at a state/local level value in terms of 












In a world of scarcity, it is important that we allocate resources where they will give 
maximum benefit – the biggest bang for the health care dollar. (Birch and Gafni, 2006) 
Economic evaluation can provide decision-makers with important information to help fulfil 
this objective. However since the early 1980s it has been identified that even though 
economic evaluation is considered useful by health economists it is not widely used by 
health care decision-makers. (Ross, 1995) Australia was the first country to make 
economic evaluation mandatory as part of the pharmaceutical reimbursement process in 
1993 and in 1995 Ross et al conducted one of the first surveys on decision-makers’ 
perceptions about use of economic evaluation.  (Drummond, 2004, Salked G, et al., 
1999)  Although more than ten years have passed it seems as though there is still a 
considerable gap between the production of economic evaluations and their use in 
decision-making. (Anell and Svarvar, 2000, Sloan and Grabowski, 1997) Numerous 
surveys have shown that the use of economic evidence faces some major obstacles in 
the local setting.  (Anell and Svarvar, 2000, Campbell and Sprague, 2001, Fijn, et al., 
1999, Luce BR and Brown RE, 1995, Odedina FT, et al., 2002, PausJenssen, et al., 
2003, Santos Ramos, et al., 1993, Sapienza AM, et al., 1998, Sarpong, 1999, Sloan, et 
al., 1997, Walkom, et al., 2006)  There is now ample evidence to suggest that having 
access to relevant economic information is a necessary but not a sufficient condition for 
its uptake.  Yet, the main reasons for producing economic evidence are i) to have it 
inform decision-making and ii) to have such decision-making processes integrated into 
local policy and, ultimately influence clinical practice so that it maximises health 
outcomes within a given resource constraint.  
 
Decisions about spending on medicines in general, not only cancer on drugs, occur at 
different levels in the Australian health care system. The Pharmaceutical Benefits 
Scheme (PBS) provides universal subsidised access to a wide range of medicines. 
(Salked G, et al., 1999). Prescription medicines are assessed by the Pharmaceutical 
Benefits Advisory Committee (PBAC), which considers cost effectiveness of medications 
in recommendations about PBS listing. (Commonwealth Department of Health and Aged 
Care, 2002) Like the PBAC in Australia, the National Institute for Health and Clinical 
Excellence (NICE) in the UK and the Canadian Common Drug Review (CDR) have had 
more success at integrating economic evidence at a national level of decision-making 
rather than local. (Drummond, 2004) In Australia, despite the importance of the 
nationally-funded PBS, local decision-makers (for example clinicians, administrators and  
 
patients) play a vital role in the distribution of medicines. Once a drug is PBS-listed, local 
decision-makers exert control over prescribing patterns and are instrumental in 
determining whether medicines are used cost-effectively. For example medications 
which are not PBS-listed, are often funded at the local level, thereby determining the 
uptake of new medicines. (Gallego G, et al., 2004) However, the use of economic 
evidence at the local level is far more ad hoc and in most cases non-existent.  (Gallego 
G, et al., 2005, Weekes and Brooks, 1996) Decision-making based on cost effectiveness 
assessment made at the national level may not translate to cost-effective use of 
medications at the local level. 
 
Local health care delivery systems, such as area health services and/or hospitals are 
under considerable pressure to fund medicines rejected, restricted or pending approval 
by the PBAC. (Gallego G, et al., 2005)  In 2005 the PBAC considered 12 cancer 
medicines and rejected six. (Australian Government. Department of Health and Ageing, 
2006) Medications that do not meet the PBS subsidy criteria are widely prescribed in the 
oncology population. (Brien, et al., 2004, Gallego G, et al., 2004, Poole and Dooley, 
2004) PBAC rejections often increase pressure on other systems (such as public 
hospitals) to fund drugs from their budgets. (Gallego G, 2006) If a drug is not listed on 
the PBS or the patient does not meet the eligibility criteria, the options are that i) patients 
can buy it as a private script or ii) public hospitals can fund it out of their own drug 
budgets for their inpatients.   It has been estimated that high cost drugs including 
oncology drugs consume up to 4% of hospital drug expenditure. (Gallego G, et al., 2004)  
 
Local decision-makers are the ones facing genuine budget constraints that impact on 
their ability to fund medicines, including scarcity in personnel, diagnostic tests, medicines 
supply, surgical procedures and bed capacity. (National Cancer Control Initiative, 2003) 
In other words, the stakes are higher at the local level; inefficient resource allocation 
decisions at the hospital setting can have an immediate and direct impact on the facility’s 
ability to treat their patients effectively and equitably. Therefore, it is not surprising that 
increasingly, cancer clinicians are called upon to discuss the economic and clinical 
aspects of a proposed treatment plan.   
 
Therefore a survey was set up to explore cancer care health care professionals’ 
knowledge, use and views of economic evaluation. It also explored their knowledge and 
views on how resource allocation decisions are made within their local area/hospital and 
whether they would value greater access to various types of economic information   
 
2. Methods  
2.1 Questionnaire development  
A survey instrument of three sections and 20 questions was developed using information 
from the literature. (Hoffmann and Graf von der Schulenburg, 2000, OECD, 2005) 
Section one sought preliminary details such as profession, job title and the reference 
group the participant belonged to (e.g. Oncology, Radiology etc.) Reference groups are 
composed by health care professionals who volunteer their time to review and edit 
cancer treatment protocols. They attend workshops throughout the year and come from 
different institutions within New South Wales (NSW). (Cancer Institute New South Wales 
(NSW), 2005) 
 
The second section asked participants about their knowledge, use and views of 
economic evaluation in decision-making. The third and final section sought information 
about participants’ knowledge and views on how resource allocation decisions were 
made within their local area/hospital. It also explored whether they would value greater 
access to various types of economic information.    
 
2.2 Data Collection  
The survey was conducted between May and August 2006. Members of CI-SCAT 
reference groups were surveyed in their capacity as health care professionals and 
decision-makers in the Australian Health Care System.  All members in the different 
reference groups (oncology, nursing, haematology and radiotherapy) were invited to 
participate. All members attending the reference groups workshops completed the 
survey.  
 
2.3 Data Analysis 
Responses were collated and analysed using the Statistical Package for the Social 
Sciences (SPSS) for Windows Version 10 (SPSS Inc., Chicago USA). Descriptive 
statistics were used to summarise data.  
 
2.4 Ethics 
This study was approved by the University Technology Sydney (UTS) Human Research 






The survey was completed by seventy four health care professionals (HCP). Table 1 
describes the participants’ characteristics.   
 
Table 1. Participants’ characteristics 
Characteristic Percentage 
% 
Reference group (n=74)   
Oncology (n=7)  9.5 
Nursing (n=43)  58.0 
Haematology (n=9)  12.0 
Radiology (n=15)  20.5 
Profession   
Specialists (n=25)  34.0 
Budgetary responsibility (n=74)   
Yes (n=37)   50.0 
No (n=37)  50.0 
Involved in making decisions about the adoption 
or financing of health technologies or treatments 
at their institution (n=74) 
 
Yes (n=36)  51.4 
No (n=38)  48.6 
 
3.1 Knowledge and views of economic evaluation 
Fourteen respondents (19%) had some training in economics/health economics. Of 
these 36% had completed coursework at a Master’s level (e.g. Public Health). Overall 
the knowledge of economic evaluation techniques seemed to be limited.  Cost 
effectiveness analysis (CEA) and cost benefit analysis (CBA) were known better than 
cost utility analysis (CUA) and cost minimisation analysis (CMA).  CBA seemed to be the 
most familiar technique.   
 
Participants with training in economics/health economics reported having better 
knowledge of CEA and CBA.   When perceptions about knowledge of all four techniques 
were combined, those with budgetary responsibilities seemed to have better knowledge 
compared to those with no budget responsibilities. (See Figure 1) 
  
 
Respondents were asked if they thought it was ethical to refuse to adopt or to finance a 
new health treatment on economic grounds at a local institution such as a hospital or 
Area Health Service. Almost half of the respondents (48%) considered it was unethical. 
The association between respondents’ characteristics and “thinking it is ethical to refuse 
or to adopt to finance a new health treatment on economic grounds at a local institution 
such as a hospital or Area Health Service” was explored (see Figure 2). Those with no 
perceived knowledge of economic evaluation and specialists were more likely to 

















   














Knowledge No knowledge Budget responsibility Involved in decision-
making
Specialist 
Yes No Not sure
 
Figure 2. Association between respondents’ characteristics and thinking it is ethical to 
refuse or to adopt to finance a new health treatment on economic grounds.  
More than half of the respondents (53%) considered that economic evidence would be a 
useful addition to the CI-SCAT website and 38% believed it would be useful in “some 
cases”.  
 
Respondents were asked to what extent they “agreed” or “disagreed” with six statements 
about the current role of economic evaluation at their institution. More than half of the 
respondents (59%) agreed that economic evaluation is a tool used infrequently by 
clinicians. Half (50%) agreed with the fact that it is a tool frequently used by managers. 
(See Figure 3) It is important to have in mind that this relates to respondents’ perceived 
knowledge about economic evaluation. Only 27% of the respondents considered that 
that economic evaluation studies are biased in favour of the technology. The majority of 
respondents (66%) considered that “clinical departments have a hard time evaluating the 
economic repercussions of the new technology”. The majority (77%) also considered 
that adequate resources are not available to conduct economic evaluation at a local 
level. One third (31%) of the respondents thought that national and international 
technology evaluation agencies have not produced effective resources for hospital 
management.  Seventy four percent of those that have or had the budgetary 





















No budget responsabilities Budget responsabilities
 
 
Figure 3. Economic evaluation is a tool infrequently used by:  
 
When participants were asked about the potential role of economic evaluation half of the 
respondents (51%) considered that evidence from economic evaluations should 
influence clinical practice.  Sixty percent considered that economic evaluations should 
inform decision-makers about which technologies are ‘good value for money’. However 
more than half of the respondents disagreed or strongly disagreed (65%) with the 
statement that economic evaluation should help contain health care spending. In 
contrast 84% agreed or strongly agreed with the fact that economic evaluation should 
identify ways to maximise health care gains within current resource constraints.  
 
Participants were asked to rate the importance of a list of factors that could influence the 
adoption of new technologies at their institution on a five point scale: from “not helpful at 
all” to “very helpful”. The most important criteria in deciding whether to adopt a new 
treatment were evidence of effectiveness/efficacy (87%) and quality/safety (89%) of the 
new technology. Indication of the morbidity associated with the illness for individual 
patients (68%), national or state wide recommendations to implement (or not implement) 
technology (59%) and organisation/professional implications (57%) were also considered 



















Cost per QALY Cost per life-year
gained
 
Figure 4. Percentage of respondents who would find the following types of evidence 
very helpful in the adoption of new technology.  
 
 
3.2 Resource allocation decisions in respondents own institution/facility 
Respondents in the oncology, nursing and haematology reference groups (n=59) were 
asked about the impact of Pharmaceutical Benefits Advisory Committee (PBAC) 
decisions and funding of medications in their institutions. Respondents in the radiologist 
groups were excluded as they are less likely to be involved in decision about access to 
medicines. The majority of respondents (86%) stated that their institution generally 
followed recommendations made by the PBAC. However more than half (53%) also 
stated that their institution may consider funding medications out of their own drug 
budget even when rejected by the PBAC. (See Table 2)  
 
 
Table 2. Access to oncology medications and role of the PBAC  
 Not 
accurate 
% ( n ) 
Accurate 
 
% ( n ) 
Not sure 
% ( n ) 
Generally follows recommendations made by PBAC  6.8 (4)  86.4 (51)  6.8 (4) 
Will await PBAC recommendations  22.0 (13)  66.1 (39)  11.9 (7) 
Will not fund drugs that have been rejected by PBAC  42.4 (25)  40.7 (24)  16.9 (10) 
May consider funding drugs out of its own drug budget 
even when PBAC has rejected the drug. 
23.7 (14)  52.5 (31)  23.7 (14) 
My institution gives clinicians freedom to determine what 
to prescribe and to whom and PBAC decisions have no 
bearing on this 
61.0 (36)  20.3 (12)  18.6 (11) 
 
Respondents were asked if the above mentioned characteristics (e.g PBAC 
recommendation) restricted prescribing. The majority of respondents (82%) considered it 
did.   
 
Participants were asked to rate the influence of the main actors when considering the 
adoption of a new drug at their institution from: “none” to “very strong”. Drug committees 
were regarded as one of the main actors in deciding if a new drug should be adopted at 
an institution. The media on the other hand was consider to have no or weak influence. 
Clinicians, heads of departments and pharmacy had strong or very strong influence. 
(See Table 3) 
 





% ( n ) 
 
Weak 
% ( n ) 
Moderate 
% ( n ) 
Strong 
% ( n ) 
Very strong 
% ( n ) 
State Government  (n=52)  19.2 (10)  13.5 (7)  21.2 (11)  9.6 (5)  36.5 (19) 
Area CEO (n=52)  21.2 (11)  13.5 (7)  23.1 (12)  19.2 (10)  23.1 (12) 
Area executive (n=51)  21.6 (11)  11.8 (6)  21.6 (11)  25.5 (13)  19.6 (10) 
Drug committee (n=55)  1.8 (1)  7.3 (4)  14.5 (8)  36.4 (20)  40.0 (22) 
Head of department or 
service (n=52) 
3.8 (2)  7.7 (4)  21.2 (11)  30.8 (16)  36.5 (19) 
Pharmacy (n=56)  7.1 (4)  7.1 (4)  25.0 (14)  35.7 (20)  25.0 (14) 
Individual clinician (n=55)  1.8 (1)  9.1 (5)  20.0 (11)  41.8 (23)  27.3 (15) 
Media (n=59)  33.3 (16)  25.0 (12)  16.7 (8)  18.8 (9)  6.3 (3) 
Other (n=5)     1.7 (1)
†  1.7 (1)*  5.1 (3)^ 
† Patient/consumer organisation 




Participants were asked to rate the level of influence of a list of factors in resource 
allocation decisions from: “none” to “very strong”. The high cost impact on local budgets 
was considered to have a very strong or strong influence in resource allocation decisions 
by the majority of respondents (83%).  Favourable evidence on clinical effectiveness 
(74%), cost effectiveness (73%) and targeting a common cancer within the population 
(73%) were also considered a very strong or strong influence by almost the same 
percentage of respondents. Factors such as intensive marketing by industry (18%) and 
cancer with a very low survival rate (49%) did not have a very strong influence.   (See 
Table 4) 
 
Table 4. Factors that influence resource allocation decisions 
Factors that influence resource 
allocation decisions 
Percentage of respondents who 
considered this factor had strong or very 
strong influence 
% 
High cost impact on the local budget   83 
Clinical effectiveness   74 
Favourable evidence on CE  73 
Targets a very common cancer   73 
Strong local clinical champion  54 
DOH strategic priorities  54 
AHS strategic priorities   47 
Strong community voice   42 
Cancer with a very low survival rate  39 
 
 
More than half of the respondents (63%) agreed/strongly agreed with the statement that 
despite operating under capped budgets, new money can usually be found.  Sixty six 
percent also agreed/strongly agreed that at their institution the concept of cost-





























The only economic criterion that tends to 
be considered is the direct financial cost 
of the new technology  n=70 
18.6  17.1   62.9  1.4  
Despite the fact that we operate under a 
capped budget, new money can usually 
be found from somewhere n=70  
39.1  15.9   43.4  1.4  
At my institution, the concept of cost-
containment is more important than cost-
effectiveness.  N=69 
17.4  13.0   66.6  2.9  
One of the barriers for taking up new 
technologies is the difficulty of moving 
resources from one sector (budget) to 
another n=70 
5.7  14.3   77.1  2.9  
Budgets are so tight that resources 
cannot be freed to adopt new 
technologies n=69 
17.4  29.0   52.2  1.4  
There are avenues where I can express 
my opinion on matters regarding resource 
allocation decisions n=71 
39.5  19.7   38  2.8  
I am not aware of the existence of a 
decision making process in our institution 
regarding the adoption of new 
technologies n=70 
37.2  18.6   34.2  7.1  
Technologies are adapted in line with 
clinical priorities n=70 






4.1 Knowledge and views of economic evaluation  
These results provide an insight into the attitudes, perceptions and knowledge of health 
care professionals involved in cancer care.    
 
In this study, a low percentage of health care professionals (HCP) had undertaken 
training in economics/health economics. These results are consistent with findings from 
previous surveys. (Hoffmann and Graf von der Schulenburg JM, 2000, Zwart-van 
Rijkom, et al., 2000) Cost benefit analysis (CBA) seemed to be the most familiar 
technique. This could be attributed to the fact that cost benefit is an expression 
commonly used to describe cost and consequences of an intervention. (Hoffmann and 





Conflicting attitudes towards economic evaluation were found. Ninety percent of 
respondents believed that economic evidence would be a useful addition to the CI-SCAT 
website (52% always and 38% at least in some cases). While fifty one percent agreed 
that evidence from economic evaluation should influence clinical practice a similar 
percentage (48%) considered it would not be ethical to refuse to fund an intervention 
based on economic evidence. Specialists were more likely to consider it was unethical to 
refuse funding based on economic evidence. Ginsburg et al found that physicians in the 
United States considered cost-effectiveness important and appropriate in clinical practice 
but they had different views as to how cost-effectiveness decisions should be 
implemented. (Ginsburg, et al., 2000) It is also important to consider that health care 
professionals do not always do what they say and even though they might consider 
economic evidence is useful they might be hesitant to apply it in practice.  (Anell and 
Svarvar, 2000, Drummond, et al., 1997, Ginsburg, et al., 2000) 
 
In this study half of the respondents (50%) considered that economic evaluation was 
used by managers to make decisions. As previously stated this is according to 
respondents’ perception of what economic evaluation is. Perhaps this could explain why 
this result differs from the literature. Previous studies have shown that the results of 
health economic evaluation are not widely used. (Duthie, et al., 1999, Hoffmann and 
Graf von der Schulenburg, 2000, Hoffmann, et al., 2002) Consistent with previous 
studies, lack of resources and expertise were identified as barriers to the use of 
economic evaluation. (Anell and Svarvar, 2000, Gallego G, et al., 2005, Hoffmann and 
Graf von der Schulenburg, 2000, Odedina FT, et al., 2002, Sloan and Grabowski, 1997, 
Spath, et al., 2003) In contrast with what has been previously reported in the literature 
only 27% of the respondents perceived studies are biased in favour of the technology.  
(Spath, et al., 2003) 
 
Respondents had a positive attitude towards the potential use of economic evaluation. 
The majority considered that economic evaluation should inform decision-makers about 
which technologies are “good value for money” and identify ways to maximise health 
care gains with current resource constraints. However, there was also evidence, of a gap 
between what health care professionals say they want and what is produced by 
economic evaluations. Ninety percent  of respondents said that they would find evidence 
about effectiveness, quality and safety useful however 47% considered cost per patient 
or the total cost of a technology useful and only 33% indicated that they would find  
 
information about the cost per QALY or the cost per life-year-saved useful. It has 
previously been reported that health economics outcomes such us QALYs are either not 
understood or consider irrelevant by clinicians. (Duthie, et al., 1999) As the latter 
information is the type typically produced by economic evaluations, this result 
emphasises the importance of: i) education and capacity-building in relation to economic 
evaluation amongst end users of the information (in this case, clinicians and decision-
makers); ii) using information understood and endorsed by clinicians and decision-
makers as inputs to the economic evaluations; and iii) making the results transparent 
and accessible to the end-users.  
 
4.2 Resource allocation decisions in participants’ own institution/facility 
The link between central and local drug funding decisions was explored. While the 
majority of respondents considered their institutions generally followed recommendations 
made by the PBAC, more than half (61%) mentioned that their institution would consider 
funding new drugs even when they had been rejected by the PBAC. It seems that when 
respondents say “yes” it means “yes” but “no” means “maybe”. There are some 
important things to consider when interpreting these results: i) economic evidence used 
to support PBS-listing has not generally been accessible to health professionals and 
patients – documentation is ‘commercial in confidence’ and generally in a format which is 
not easy to understand (Marley J, 1996) ii) medicines used for in-patients in public 
hospitals are primarily funded by the hospital (Commonwealth Department of Health and 
Aged Care, 2000) and iii) public hospital decision-makers perceived that studies 
conducted from the hospital perspective will be more useful.  (Gallego G, et al., 2005)  It 
has been previously identified that decision-makers at the local level deal with 
identifiable patients and there is a considerably different emotional response. (Gallego 
G, 2006) 
 
If it is assumed that decision-makers at the local level will rarely be able to use the 
results of economic evaluation (Weatherly, et al., 2002) the influence of PBAC decisions 
at the local level should be further explored.  
 
This survey also explored who influences the adoption of new drugs and technologies at 
the local level. Not surprisingly Drug and Therapeutic Committees (DTCs), heads of 
departments and the state government were rated as having a strong influence when it 
comes to new drugs. This can be explained by the present drug funding arrangements. 
Currently the State-based public hospital medicines funding is included as part of the  
 
financial grants from the Commonwealth to the States. This means it depends on 
budgetary allocation decisions made at a number of levels including the health 
department, health district or area health service and individual hospital. (Salked G, et 
al., 1999, The Society of Hospital Pharmacists of Australia (SHPA), 2004) 
 
As previously reported in the literature, cost is a major driver in decisions about the 
allocation of resources. Eighty three percent of the respondents considered it had a 
strong influence and 62% agreed/strongly agreed with the statement that the only 
economic criterion that tends to be considered is the direct financial cost of the new 
technology. Clinical effectiveness was also rated high by 74%. (Fijn, et al., 1999, 
Jenkings KN and Barber N, 2004, Martin DK, et al., 2003, PausJenssen, et al., 2003, 
Spath, et al., 2003) 
 
Respondents also considered that budgets are inflexible (72%) and too tight (56%) 
resulting in little capacity for resources to be used for the adoption of new technologies. 
This “drug budget silo mentality” previously described by Drummond et al. (de 
Pouvourville, et al., 2005) as well as the fragmentation of the funding system for 
pharmaceuticals in Australia, (Doecke C, 2005, Plumridge R, 2003) hinders the role of 
economic evaluation at the local setting. Instead there are perverse incentives to cost-
shift and offload cost rather than work in the interest of the overall health system. (Hall J, 
1999) Cost shifting is a well established practice, but is reactive and will be practised 
more widely as regulatory requirements or agreements are changed. This leads to 
administrative inefficiencies, inequitable access and, ultimately, the potential for worse 
health outcomes. (Hall J, 1999) It could be perceived that this is something unique to the 
Australian health care system however cost shifting of expensive treatments from 
secondary to primary care has also been described in the UK. (Crump BJ, et al., 1995, 
Orme M, 1991) 
 
5. Limitations 
A well known limitation of surveys such as the one presented here is that health care 
professionals do not always do what they say and their stated demand for information 
does not always match actual demand. (Anell and Svarvar, 2000, Drummond, et al., 
1997, Ginsburg, et al., 2000) There may also be a sample bias as participants belonged 
to a reference group and are already interested in best practice. However if this were the 
case we might be underestimating the challenges of bringing economic evidence into 
local decision-making.  
 
 
6. Conclusions  
Providing economic evidence is necessary but by no means sufficient condition to 
ensure its use. It is important to develop a decision-making process that can absorb 
economic evidence. It is important to work with decision-makers to provide relevant local 
evidence that is consistent with economic principles. As stated by Drummond any 
attempt to use economic evaluation at the local level needs to take into account the 
decision-maker’s objectives. (Drummond, 2004)  
 
Future research will develop and explore models of best practice on how to incorporate 
economic evidence into the CI-SCAT cancer protocols by collaborating with the health 
care professionals in the CI-SCAT reference groups.   
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